In preparation for my role in warming up for Noam Chomsky on WORTFM Madison Wisconsin today, I put together this FAQ on the TPP ISDS leak and intellectual property policy concerns. As with all our posts, this is a CC-By…
The table linked below compares the full text of Title XXII of the Trade Act of 2002, ( the last Trade Promotion Authority law, which expired in 2007); the Bipartisan Congressional Trade Priorities Act of 2014; and the Bipartisan Congressional…
This presentation is in the IP room. But my message is for the IP team to be talking to the ISDS folks next door. The reason is that there is an increasingly urgent need revise the EU and US ISDS…
[Cross posted from the American Constitutional Society blog, Link] The Trade Promotion Authority (TPA) bill that was released last week contains a fascinating Section 8 on “Sovereignty.” The section appears intended to make all trade agreements with the U.S. not…
Trade Promotion Authority legislation was introduced in the House and Senate today. The full text is available here. Trade Promotion Authority lets Congress set trade negotiating objectives for the executive branch, and in return, the legislature agrees that it will…
Introduction: Recently the United States Trade Representative (USTR) released a memo to reporters with Q&A’s on Investor-to-State Dispute Settlement (ISDS). ISDS is a mechanism by which foreign investors can challenge national governments, alleging that the government violated their investor rights.…
January 26, 2015 | 9:30 – 2:30 American University School of International Service Printable agenda & directions (PDF) Co-hosted by the AU School of International Service and AU Washington College of Law’s Program on International Organizations, Law and Diplomacy The…
[Médecins Sans Frontières Access Campaign] The European Union’s (EU) free trade and research and development (R&D) policies promote excessive intellectual property (IP) protection. This approach jeopardises access to affordable, needed medicines and impedes needs-driven biomedical innovation. Médecins Sans Frontières Access…
Brand name pharmaceutical companies are advocating for inclusion of disciplines on public pharmaceutical reimbursement programs in the ongoing negotiations of the Trans-Pacific Partnership agreement (TPP) and the Transatlantic Trade and Investment Partnership (TTIP) trade agreements. This post answers some frequently asked questions…
Oxfam press release, Link Insufficient innovation and a lack of access to affordable medicines are major barriers to achieving the right to health in low- and middle-income countries. This paper argues that European Union trade policies should not be used…
Cross posted from Public Citizen’s Eye’s on Trade. Link. In an op-ed appearing in Forbes on Tuesday, the CEO of Eli Lilly, a U.S. pharmaceutical corporation, paints a glowing picture of how the proposed Trans-Atlantic Free Trade Agreement (TAFTA) would…
As Trans Pacific Partnership (TPP) negotiators began this week’s round of talks in Hanoi, the International Chamber of Commerce issued a white paper urging the inclusion of strong trade secret provisions in the agreement. “Trade Secrets: Tools for Innovation and…